Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

被引：3849
|
作者：
Fischereder, Michael [1 ]
Schoenermarck, Ulf [1 ]
机构：
[1] Klinikum Ludwig Maximilians Univ Munich, Munich, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 11期
关键词：
D O I：
10.1056/NEJMc1600827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1092 / 1093
页数：2
相关论文
共 50 条
  • [1] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
  • [2] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
  • [3] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2117 - 2128
  • [4] Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus
    Jaeschke, Roman
    Gerstein, Hertzel
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 803 - 805
  • [5] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes REPLY
    Zinman, Bernard
    Lachin, John M.
    Inzucchi, Silvio E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1094 - 1094
  • [6] Empagliflozin and cardiovascular outcomes in type 2 diabetes
    Gregory B. Lim
    [J]. Nature Reviews Cardiology, 2016, 13 (1) : 3 - 3
  • [7] Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
    Guthrie, Robert
    [J]. POSTGRADUATE MEDICINE, 2016, 128 (04) : 335 - 337
  • [8] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [9] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Inzucchi, Silvio E.
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans Juergen
    Broedl, Uli C.
    Zinman, Bernard
    [J]. CIRCULATION, 2015, 132 (23) : 2271 - 2271
  • [10] MODELING CARDIOVASCULAR OUTCOMES OF TREATMENT WITH EMPAGLIFLOZIN IN TYPE 2 DIABETES BASED ON HARD OUTCOMES DATA
    Kansal, A.
    Zheng, Y.
    Proskorovsky, I
    Krotneva, S.
    Kandaswamy, P.
    Ruffolo, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
12345